Choosing a hinged implant in the revision knee arthroplasty (rTKA) setting is challenging and limited data on implant performance exists. We present the survivorship and reason for failure in rTKA performed at our institution using the LINK hinge prosthesis, predominantly the cemented modular Endo-Model prosthesis. 260 consecutive revision knee cases performed between 2012 and 2020 were reviewed retrospectively. Mean follow up was 27 months (range 0 to 107). Survivorship was analysed in Stata using a Log Rank test to compare performance in patients stratified according to age (≥80 years old (76 cases), 70–79 years (104 cases) and ≤70 years (80 cases).Abstract
Introduction
Methodology
Allogeneic blood transfusion is associated with complications and significant cost. The RD&E has looked at the use of autologous drains to decrease the frequency of allogeneic transfusion after our study of 100 cases showed an improved post-operative haemoglobin and reduced length of stay. In 2007 a protocol to identify those patients of increased need for an autologous drain was made using a study of 191 cases showed an average haemoglobin drop post-operatively of 3.05g/dl and average intra-operative blood loss of 285 ml. This protocol gave triggers for autologous drain use; preoperative haemoglobin of <13g/dl, intra-operative blood loss >400ml, tourniquet use, patient weight <50kg and patients refusing donated blood. In 2007-08, 65% of a further 275 cases analysed met the triggers for use of an autologous system. The remaining patients received low vacuum drains. Of the 275 patients, only 2 (<1%) of those who did not fulfil the criteria for an autologous drain required allogeneic blood, compared with 43 patients (24%) of those deemed high risk of transfusion, and assigned autologous drains. The protocol was successful in identifying those patients who required additional support and expenditure to minimise allogeneic blood transfusion. Analysis of this data led to recommended changes to the protocol in order to maximise the efficiency of the autologous drain use. Due to the increased cost of autologous drains (£68) compared with the low vacuum systems (£32), and the cost of allogeneic units at £141, the expenditure per patient was calculated and shown to fall from £92 in 2007 to £78 in a further patient cohort in 2010. In conclusion, this protocol allows the clinician to appropriately target the use of the more expensive autologous drains to those of increased risk of transfusion. This helps to minimise unnecessary allogeneic transfusion, and this has been shown to be cost effective.
